Cerity Partners
IRMD icon

Cerity Partners’s iRadimed IRMD Stock Holding History

Cerity Partners’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$319K Buy
3,313
+634
+24% +$63.4K ﹤0.01% 2567
2025
Q4 		$261K Buy
+2,679
New +$230K ﹤0.01% 2490

Other funds holding IRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cerity Partners's IRMD Position: Q1 2026 in Review

Cerity Partners increased its iRadimed (IRMD) stake by 24% in Q1 2026, buying an estimated $63.4K and bringing the position to 3,313 shares worth $319K. The position accounts for ﹤0.01% of the portfolio, ranked #2567.

Cerity Partners first reported a position in IRMD in Q4 2025 and has held it in 2 quarters since. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Cerity Partners held 3,313 shares of iRadimed worth $319K as of Q1 2026.
  • Cerity Partners bought 634 iRadimed shares in Q1 2026, an estimated $63.4K.
  • iRadimed made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #2567 holding.
  • Cerity Partners first reported a position in iRadimed in Q4 2025 and has held it in 2 quarters since.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.